(Q28193081)

Paul W Armstrong

9

0 references

Robert Califf

2

Robert M Califf

0 references

Christopher B. Granger

6

Christopher B Granger

0 references

Vic Hasselblad

8

Vic Hasselblad

0 references

Robert A Harrington

4

Robert A Harrington

0 references

L Kristin Newby

1

L Kristin Newby

0 references

Harvey D. White

3

Harvey D White

0 references

author name string

R John Simes

American Journal of Medicine

7

0 references

language of work or name

English

0 references

publication date

1 June 2002

0 references

published in

0 references

volume

112

0 references

issue

8

0 references

page(s)

647-58

0 references

cites work

Are we mortgaging the medical profession?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

A critical appraisal of platelet glycoprotein IIb/IIIa inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Aspirin as an antiplatelet drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Platelet-active drugs: the relationships among dose, effectiveness, and side effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Prior aspirin use predicts worse outcomes in patients with non–ST-elevation acute coronary syndromes11This study was sponsored by COR Therapeutics Inc., South San Francisco, California; and Schering-Plough Research Institute, Kenilworth, New Jersey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Profile and prevalence of aspirin resistance in patients with cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Design of the Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Thrombi in acute coronary syndromes : revisited and revised

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Cell adhesion molecules in coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Characterization of integrin-tetraspanin adhesion complexes: role of tetraspanins in integrin signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Expression of ligand-induced binding sites on glycoprotein IIb/IIIa complexes and the effect of various inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Atherosclerosis — An Inflammatory Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Effects of abciximab, ticlopidine, and combined Abciximab/Ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

RGD peptides induce apoptosis by direct caspase-3 activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Normal and abnormal consequences of apoptosis in the human heart. From postnatal morphogenesis to paroxysmal arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Platelet PlA2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Glycoprotein IIIa PlA1/A2 polymorphism and sudden cardiac death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

PlA2 polymorphism and efficacy of aspirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3

Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901106-3